Fresh off winning a $20 million Ebola treatment contract from the Department of Health and Human Services, Gaithersburg, Md.-based Emergent BioSolutions (NYSE: EBS) has been awarded another contract, this time from Centers for Disease Control and Prevention (CDC).
The biodefense company announced that the CDC has exercised an option to increase its supply of Vaccinia Immune Globulin (VIGIV), a smallpox vaccine.
This portion of the contract is worth $44 million, increasing the total contract value to $80 million. Through the purchase of Cangene Corporation in February 2014, Emergent BioSolutions was able to secure the contract and continue to supply the smallpox vaccine which got FDA approval in 2005.
Emergent BioSolutions stock was stable in early morning trading, down less than one percent. The market capitalization of the company is approximately $1.32 billion.